NCT03634982 2022-09-01Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsRevolution Medicines, Inc.Phase 1 Unknown133 enrolled
NCT03083743 2017-03-20A Phase III Trial of Recombinant Human Apo-2 Ligand for InjectionShanghai Gebaide Biotechnology Co., Ltd.Phase 3 Unknown417 enrolled